AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03024060 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IBL 20 mW
Description: 10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
Study NCT03024060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IBL 10 mW
Description: 10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
Study NCT03024060 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IBL 10 mW
Description: 10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
Study NCT06792240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron supplementation
Description: The amount of supplementary iron was decided for patients according to the daily requirement (8- 18 mg / day), according to LARN 2012 and (RDAs) for Iron. (25) . This study took in consideration also, the recommendation of the National Institutes of Health iron dietary supplement fact of sheet as reference to calculate iron dose for our candidates because this dose isn't against LARN and more practical to applicate.~The minimum RDA values is applied, which coincides within the LARN daily requirement limits. (7 mg-18 mg of iron per day). Applying the minimum recommended RDA dose, that can satisfy the daily iron requirement by age, approximating it to be adequate for the clinical dose administered orally once a day (e.g. 1.98 g ==> 2 g, 1.53 g ==> 1.5 g
Study NCT06792240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: control group
Description: Non intervension: Only restricted low and controlled Phe diet therapy
Study NCT00510367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m\^2 By Vein Daily x 2 Days
Study NCT00510367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 By Vein On Day 1
Study NCT00510367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 By Vein Over 72 Hours
Study NCT00757367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI Inhalation Powder
Description: 1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
Study NCT00110591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: Monoclonal antibody to CCR5
Study NCT02957669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Self-Regulation
Description: PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
Study NCT02957669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy Practice Group
Description: Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
Study NCT00143637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Office dust
Description: airborne office dust spiked with glucan
Study NCT00110591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRO 140
Description: Monoclonal antibody to CCR5
Study NCT04572698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY09004
Description: LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
Study NCT04572698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea
Description: EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
Study NCT02719457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6 minute walk test (6 MWT)
Description: 6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
Study NCT02719457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spot marching test (SMT)
Description: Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
Study NCT05240963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporal PEEK implant
Description: Temporal PEEK implant to reconstruct temporal fossa after temporalis muscle transfer
Study NCT00445341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavopiridol
Description: Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
Study NCT01203124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
Study NCT00143637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clean air
Description: Clean air
Study NCT04589806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2-stage ridge splitting
Description: two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
Study NCT01073033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk supplement 1
Description: milk supplement with probiotics
Study NCT01203124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01073033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk supplement 2
Description: milk supplement without probiotics
Study NCT02140086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buteyko based Remedial Breathing Therapy
Description: Buteyko based remedial Breathing Therapy after Dr. Buteyko
Study NCT01203124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03093883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrinemia
Description: Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study NCT03093883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer
Description: Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Study NCT01201850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin®)
Description: Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
Study NCT01600469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-B
Description: 250-1500 mg/day, oral, for 24 weeks
Study NCT01600469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, oral, for 24 weeks
Study NCT03442205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC + LCBDE + ENBD + primary closure of CBD
Description: LC + LCBDE + ENBD + primary closure of CBD
Study NCT03442205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP technique + LC
Description: ERCP technique + LC
Study NCT03442205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC + LCBDE + primary closure of CBD
Description: LC + LCBDE + primary closure of CBD
Study NCT01616069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine and levosimendan
Description: epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
Study NCT01156363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis
Description: regular haemodialysis or peritoneal dialysis
Study NCT01156363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: once monthly, subcutaneously or intravenously, for 32 weeks
Study NCT04880993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg tablets
Description: Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
Study NCT04880993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Farxiga® 10 mg tablets
Description: Manufactured by AstraZeneca Pharmaceuticals LP
Study NCT00985738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
Study NCT00985738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
Study NCT02262338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-182
Description: Recombinant HIRMAb-IDS
Study NCT00981682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120
Description: once a day treatment of nocturia
Study NCT02617329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
Study NCT02617329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cervical flexion
Description: Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
Study NCT02945306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Study NCT02945306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Watchful waiting with supportive care
Description: Use of widely prescribed medicines to treat associated conditions
Study NCT00004604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA RNA-pulsed DC cancer vaccine
Description: carcinoembryonic antigen RNA-pulsed dendritic cells
Study NCT03152396 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CV risk assessment and modification of global risk
Description: Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
Study NCT02303366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiosurgery (SABR)
Description: Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
Study NCT02303366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
Study NCT03571503 — intervention group
Intervention type: PROCEDURE
Intervention: Doin (conduction exercise)
Description: An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
Study NCT03571503 — intervention group
Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Study NCT03571503 — intervention group
Intervention type: PROCEDURE
Intervention: Chuna manual therapy
Description: Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
Study NCT03571503 — intervention group
Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
Study NCT03571503 — intervention group
Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
Study NCT03571503 — intervention group
Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Study NCT03571503 — intervention group
Intervention type: PROCEDURE
Intervention: Electroacupuncture
Description: Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Study NCT03571503 — intervention group
Intervention type: PROCEDURE
Intervention: Cupping
Description: Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
Study NCT03571503 — intervention group
Intervention type: OTHER
Intervention: Other intervention(s)
Description: Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
Study NCT03733899 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Minims Proxymetacaine hydrochloride Eye Drops
Study NCT01318993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 milligrams twice daily
Study NCT00864331 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: 39 Gy in 13 daily fractions of 3 Gy
Study NCT00864331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy
Description: Chemotherapy followed by low dose palliative radiotherapy
Study NCT03733899 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride Solution
Study NCT00864331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy given alone
Study NCT03136900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrilon without lactose® fortified by concentration
Description: enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
Study NCT02390687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study NCT03136900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrilon without lactose® fortified by Maltodextrin and oil supplementation
Description: enteral diet with cow milk protein-based infant formula without lactose 14%
Study NCT03191812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
Study NCT03191812 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
Study NCT04379947 — intervention group
Intervention type: PROCEDURE
Intervention: Fractional Flow reserve
Description: Measurement of fractional flow reserve in the preoperative work-up for oronary artery bypass surgery
Study NCT00608842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.
Study NCT00608842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching vehicle placebo administered via intralipomal injection.
Study NCT04583969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzilumab
Description: Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
Study NCT04583969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
Study NCT04583969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Study NCT04583969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Study NCT00971360 — intervention group
Intervention type: OTHER
Intervention: conversion disorder
Description: Proinflammatory cytokine levels in conversion disorder
Study NCT00864331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy and chemotherapy
Description: Low dose palliative radiotherapy followed by chemotherapy
Study NCT00356291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skill-Building (SB) plus Motivational Interviewing
Description: SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
Study NCT00356291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skill-Building (SB)
Description: SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
Study NCT02548780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver.